PAK1

Serine/threonine-protein kinase PAK 1 · Q13153 · PAK1 on Sugi Atlas →

42,287 patent compounds predicted against PAK1, 25,525 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL298435	0.51	17/20
SCHEMBL298434	0.56	15/20
SCHEMBL299488	0.54	15/20
SCHEMBL299093	0.56	13/20
SCHEMBL298248	0.56	12/20
SCHEMBL297940	0.53	12/20
SCHEMBL298226	0.51	12/20
SCHEMBL298249	0.55	10/20
SCHEMBL261580	0.47	10/20
SCHEMBL261581	0.47	10/20
Hydrochloric Acid (SCHEMBL259745)	0.40	10/20
Hydrochloric Acid (SCHEMBL259746)	0.40	10/20
SCHEMBL311403	0.44	9/20
SCHEMBL260585	0.41	9/20
SCHEMBL260586	0.41	9/20
Hydrochloric Acid (SCHEMBL260509)	0.40	9/20
Hydrochloric Acid (SCHEMBL259860)	0.39	9/20
Hydrochloric Acid (SCHEMBL259861)	0.39	9/20
Hydrochloric Acid (SCHEMBL260228)	0.37	9/20
Hydrochloric Acid (SCHEMBL260229)	0.37	9/20

Clinical trials — most relevant to PAK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation	PHASE1/PHASE2	RECRUITING
A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer	PHASE2	COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
Safety and Feasibility of Metformin for Sepsis Induced AKI	PHASE2	COMPLETED
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer	PHASE2	COMPLETED
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)	PHASE2	COMPLETED
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals	PHASE1/PHASE2	COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer	PHASE2	COMPLETED
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)	PHASE1/PHASE2	UNKNOWN
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	PHASE2	UNKNOWN
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)	PHASE2	WITHDRAWN
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC	nan	UNKNOWN
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PAK1 binder may also engage these)

Protein	Name	Similarity
P35465	—	1.000	P35465 →
Q08E52	—	1.000	Q08E52 →
Q8AXB4	—	1.000	Q8AXB4 →
O88643	—	1.000	O88643 →
PAK3	Serine/threonine-protein kinase PAK 3	1.000	landscape →
Q7YQL3	—	1.000	Q7YQL3 →
Q7YQL4	—	1.000	Q7YQL4 →
PAK2	Serine/threonine-protein kinase PAK 2	1.000	landscape →
Q8CIN4	—	1.000	Q8CIN4 →
Q17850	—	1.000	Q17850 →
Q64303	—	1.000	Q64303 →
Q62829	—	1.000	Q62829 →
Q29502	—	1.000	Q29502 →
Q61036	—	0.998	Q61036 →
Q9NB31	—	0.995	Q9NB31 →
A4K2M3	—	0.994	A4K2M3 →
A4K2Y1	—	0.993	A4K2Y1 →
Q9JI10	—	0.993	Q9JI10 →
DCLK1	Serine/threonine-protein kinase DCLK1	0.993	landscape →
O61125	—	0.992	O61125 →
Q4KSH7	—	0.992	Q4KSH7 →
Q5E9L6	—	0.992	Q5E9L6 →
P13234	—	0.992	P13234 →
STK4	Serine/threonine-protein kinase 4	0.992	landscape →
Q802A6	—	0.992	Q802A6 →
A4K2T0	—	0.992	A4K2T0 →
A4K2P5	—	0.992	A4K2P5 →
A4K2Q5	—	0.992	A4K2Q5 →
Q99JT2	—	0.992	Q99JT2 →
A4K2W5	—	0.992	A4K2W5 →